Tanox to Present Two Abstracts on TNX-355 at 2005 ICAAC
Posted on: Monday, 7 November 2005, 15:00 CST
HOUSTON, Nov. 7 /PRNewswire-FirstCall/ -- Tanox, Inc. will present two abstracts on its novel HIV antibody, TNX-355, at the American Society for Microbiology's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Dec. 16-19, 2005 in Washington, D.C.
The presentations include a late-breaking submission that will further highlight the drug candidate's recently announced Phase 2 Week 24 efficacy results. A second abstract will detail TNX-355's activity against CXCR4 and CCR5 tropic viruses. Additionally, results of in vitro combination studies with enfuvirtide will be highlighted.
Phase 2 clinical results showed that TNX-355, when combined with an optimized background regimen, produced a considerably greater reduction in viral load in HIV-infected patients than did placebo in combination with optimized background therapy. The 82-patient clinical trial met its primary endpoint and is continuing to its planned 48-week duration.
About TNX-355
TNX-355 is a humanized monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing the entry of HIV particles into lymphocytes. TNX-355 is the first antibody in development for the treatment of HIV and AIDS. A Phase 2 clinical study demonstrated that TNX-355, plus optimized background therapy, produces a clinical meaningful reduction in viral load against multiple strains of HIV, without depleting CD4-positive cells. TNX-355 was fast tracked by the Food and Drug Administration in 2003. The fast track designation is designed to expedite approval of therapies for life-threatening diseases and allows for rolling new drug application (NDA) submissions.
About Tanox, Inc.
Tanox is a biotechnology company specializing in the discovery and development of biotherapeutics based on monoclonal antibody technology. The company develops innovative therapeutic agents for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first anti-immunoglobulin E (anti-IgE) antibody to be brought to market. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG. Additional corporate information is available at http://www.tanox.com/ .
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGOPRN Photo Desk photodesk@prnewswire.com
Tanox, Inc.
CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, orssievert@tanox.com
Web site: http://www.tanox.com/
Source: PRNewswire-FirstCall
Related Articles
- Promising New HIV-AIDS Drug, 1st in New Class, Approved for Canadian Market
- AVI BioPharma Announces Positive Clinical Trial Results Delivering NEUGENE Antisense Drugs to the Central Nervous System
- Tanox Conducts Meeting With Food and Drug Administration Regarding Its HIV/AIDS Antibody, TNX-355
- Amazon Biotech Initiates Negotiations Subsequent to Receiving "Go Ahead" From FDA for Phase I/II HIV Clinical Trial
- Clinical Trial Shows Device Optimizes Cardiac Resynchronization Therapy in Less Than Two Minutes; St. Jude Medical Announces QuickOpt Optimization Clinical Trial Results and European Regulatory Approvals at Cardiostim 2006
- WHO seeks greater openness in clinical drug trials
- WayPoint Biomedical Launches New Range of Clinical Drugs of Abuse Rapid Tests
- St. Jude Medical Announces Publication of OPTIC Clinical Study Results in JAMA; Study May Hold the Key to Reducing Shocks in ICD Patients
- Rockville-Based EntreMed Inc. Obtains Two New Patents for Its Lead Clinical Drug Candidate
- Clinical Trial Results May Boost ImClone
 |
 |
User Comments (0)
RSS Feeds